Literature DB >> 25338544

Receptor-mediated uptake of boron-rich neuropeptide y analogues for boron neutron capture therapy.

Verena M Ahrens1, René Frank, Solveig Boehnke, Christian L Schütz, Gabriele Hampel, Dorothée S Iffland, Nicolas H Bings, Evamarie Hey-Hawkins, Annette G Beck-Sickinger.   

Abstract

Peptidic ligands selectively targeting distinct G protein-coupled receptors that are highly expressed in tumor tissue represent a promising approach in drug delivery. Receptor-preferring analogues of neuropeptide Y (NPY) bind and activate the human Y1 receptor subtype (hY1 receptor), which is found in 90% of breast cancer tissue and in all breast-cancer-derived metastases. Herein, novel highly boron-loaded Y1 -receptor-preferring peptide analogues are described as smart shuttle systems for carbaboranes as (10) B-containing moieties. Various positions in the peptide were screened for their susceptibility to carbaborane modification, and the most promising positions were chosen to create a multi-carbaborane peptide containing 30 boron atoms per peptide with excellent activation and internalization patterns at the hY1 receptor. Boron uptake studies by inductively coupled plasma mass spectrometry revealed successful uptake of the multi-carbaborane peptide into hY1 -receptor-expressing cells, exceeding the required amount of 10(9) boron atoms per cell. This result demonstrates that the NPY/hY receptor system can act as an effective transport system for boron-containing moieties.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  boron neutron capture therapy; cellular uptake; neuropeptide Y; peptides; solid-phase synthesis

Mesh:

Substances:

Year:  2014        PMID: 25338544     DOI: 10.1002/cmdc.201402368

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  5 in total

Review 1.  Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies.

Authors:  Ricardo Ribeiro; Eugénia Pinto; Carla Fernandes; Emília Sousa
Journal:  Mar Drugs       Date:  2022-06-15       Impact factor: 6.085

2.  Ruthenacarborane-Phenanthroline Derivatives as Potential Metallodrugs.

Authors:  Martin Kellert; Imola Sárosi; Rajathees Rajaratnam; Eric Meggers; Peter Lönnecke; Evamarie Hey-Hawkins
Journal:  Molecules       Date:  2020-05-15       Impact factor: 4.411

3.  Shuttling of Peptide-Drug Conjugates by G Protein-Coupled Receptors Is Significantly Improved by Pulsed Application.

Authors:  Isabelle Ziffert; Anette Kaiser; Paul Hoppenz; Karin Mörl; Annette G Beck-Sickinger
Journal:  ChemMedChem       Date:  2020-09-03       Impact factor: 3.466

4.  Neuropeptide Y receptors: a promising target for cancer imaging and therapy.

Authors:  Juan Li; Yuchen Tian; Aiguo Wu
Journal:  Regen Biomater       Date:  2015-08-07

Review 5.  Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.

Authors:  Paul Hoppenz; Sylvia Els-Heindl; Annette G Beck-Sickinger
Journal:  Front Chem       Date:  2020-07-07       Impact factor: 5.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.